Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 7/2016

01-07-2016 | Review

Major apoptotic mechanisms and genes involved in apoptosis

Authors: Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, Yusuf Baran

Published in: Tumor Biology | Issue 7/2016

Login to get access

Abstract

As much as the cellular viability is important for the living organisms, the elimination of unnecessary or damaged cells has the opposite necessity for the maintenance of homeostasis in tissues, organs and the whole organism. Apoptosis, a type of cell death mechanism, is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body. Apoptosis can be triggered by intrinsically or extrinsically through death signals from the outside of the cell. Any abnormality in apoptosis process can cause various types of diseases from cancer to auto-immune diseases. Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family of genes, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis. In this review, we discuss the basic features of apoptosis and have focused on the gene families playing critical roles, activation/inactivation mechanisms, upstream/downstream effectors, and signaling pathways in apoptosis on the basis of cancer studies. In addition, novel apoptotic players such as miRNAs and sphingolipid family members in various kind of cancer are discussed.
Literature
1.
Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2013;35:495–516.CrossRef
2.
Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239–57.PubMedPubMedCentralCrossRef
3.
4.
Horvitz HR. Genetic control of programmed cell death in the nematode Caenorhabditis elegans. Cancer Res. 1999;59:1701–6.
5.
Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;10:1456–62.CrossRef
6.
Krauss G. Biochemistry of signal transduction and regulation. Ed:VCH Wiley, 3rd Edition. 2003;511–531.
7.
Power C, Fanning N, Redmond HP. Cellular apoptosis and organ injury in sepsis: a review. Shoch. 2002;18:197–211.CrossRef
8.
9.
Rosenblatt J, Raff MC, Cramer LP. An epithelial cell destined for apoptosis signals its neighbors to extrude it by an actin- and myosin-dependent mechanism. Curr Biol. 2011;11:1847–57.CrossRef
10.
Ferri KF, Kroemer G. Organelle-specific initiation of cell death pathways. Nat Cell Biol. 2001;3:255–63.CrossRef
11.
12.
Liu X, Li P, Widlak P, et al. The 40-kDa subunit of DNA fragmentation factor induces DNA fragmentation and chromatin condensation during apoptosis. Proc Natl Acad Sci U S A. 1998;95:8461–6.PubMedPubMedCentralCrossRef
13.
Grimsley C, Ravichandran KS. Cues for apoptotic cell engulfment: eat-me, don’t-eat-me and come-get-me signals. Trends Cell Biol. 2003;13:648–56.PubMedCrossRef
14.
Mashima T, Naito M, Noguchi K, Miller DK, Nicholson DW, Tsuruo T. Actin cleavage by CPP-32/apopain during the development of apoptosis. Oncogene. 1997;14:1007–12.PubMedCrossRef
15.
Ziegler U, Groscurth P. Morphological features of cell death. Physiology. 2004;10:124–8.CrossRef
16.
Wang X. The expanding role of mitochondria in apoptosis. Genes Dev. 2001;15:2922–33.PubMed
17.
18.
19.
Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 2005;55:178–94.PubMedCrossRef
20.
Saelens X, Festjens N, Vande Walle L, van Gurp M, van Loo G, Vandenabeele P. Toxic proteins released from mitochondria in cell death. Oncogene. 2004;23:2861–74.PubMedCrossRef
21.
Du C, Fang M, Li Y, Li L, Wang X. SMAC, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 2000;102:33–42.PubMedCrossRef
22.
23.
Hill MM, Adrain C, Duriez PJ, Creagh EM, Martin SJ. Analysis of the composition, assembly kinetics and activity of native Apaf-1 apoptosomes. Embo J. 2004;23:2134–45.PubMedPubMedCentralCrossRef
24.
25.
Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2:647–56.PubMedCrossRef
26.
Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104:487–501.PubMedCrossRef
27.
Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell. 1995;81:495–50.PubMedCrossRef
28.
29.
Sax JK, Fei P, Murphy ME, Bernhard E, Korsmeyer SJ, El-Deiry WS. BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol. 2002;4:842–9.PubMedCrossRef
30.
Hitoshi Y, Lorens J, Kitada SI, et al. Toso, a cell surface, specific regulator of Fas-induced apoptosis in T cells. Immunity. 1998;8:461–71.PubMedCrossRef
31.
Scaffidi C, Schmitz I, Krammer PH, Peter ME. The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem. 1999;274:1541–8.PubMedCrossRef
32.
Kuranaga E. Beyond apoptosis: caspase regulatory mechanisms and functions in vivo. Genes Cells. 2012;17:83–97.PubMedCrossRef
33.
Yuan J, Shaham S, Ledoux S, Ellis HM, The HHR. The C. elegans cell death gene Ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. Cell. 1993;75:641–52.PubMedCrossRef
34.
Ellis HM, Horvitz HR. Genetic control of programmed cell death in the nematode C. elegans. Cell. 1986;44:817–29.PubMedCrossRef
35.
Shi Y. Mechanisms of caspase inhibition and activation during apoptosis. Mol Cell. 2002;9:459–70.PubMedCrossRef
36.
Chowdhury I, Tharakan B, Bhat GK. Caspases—an update. Comp Biochem Physiol. 2008;151:10–27.CrossRef
37.
Yan N, Shi Y. Mechanisms of apoptosis through structural biology. Annu Rev Cell Dev Biol. 2005;21:35–56.PubMedCrossRef
38.
Los M, Stroh C, Janicke RU, Schulze-Osthoff K. Caspases: more than just killers? Trends Immunol. 2001;22:31–4.PubMedCrossRef
39.
Martinon F, Tschopp J. Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell. 2004;117:561–74.PubMedCrossRef
40.
Los M, van de Craen M, Penning CL, et al. Requirement of an ICE/CED-3 protease for Fas/APO-1-1 mediated apoptosis. Nature. 1995;37:81–3.CrossRef
41.
Fantuzzi G, Puren AJ, Harding MW, Livingston DJ, Dinarello CA. Interleukin-18 regulation of interferon gamma production and cell proliferation as shown in interleukin-1beta-converting enzyme (caspase-1)-deficient mice. Blood. 1998;91:2118–25.PubMed
42.
Vakifahmetoglu-Norberg H, Zhivotovsky B. The unpredictable caspase-2: what can it do? Trends Cell Biol. 2010;20:150–9.PubMedCrossRef
43.
Paroni G, Henderson C, Schneider C, Brancolini C. Caspase-2-induced apoptosis is dependent on caspase-9, but its processing during UV- or tumor necrosis factor-dependent cell death requires caspase-3. J Biol Chem. 2001;276:21907–15.PubMedCrossRef
44.
Van de Craen M, Declercq W. Van den brande I, Fiers W, Vandenabeele P. The proteolytic procaspase activation network: an in vitro analysis. Cell Death Differ. 1999;6:1117–24.PubMedCrossRef
45.
Tinel A, Tschopp J. The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science. 2004;304:843–6.PubMedCrossRef
46.
47.
Porter AG, Janicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999;6:99–104.PubMedCrossRef
48.
Slee EA, Adrain C, Martin SJ. Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J Biol Chem. 2001;276:7320–6.PubMedCrossRef
49.
50.
Lamkanfi M, Kanneganti TD. Caspase-7: a protease involved in apoptosis and inflammation. Int J Biochem Cell Biol. 2010;42:21–4.PubMedCrossRef
51.
Ghavami S, Eshraghi M, Kadkhoda K, et al. Role of BNIP3 in TNF-induced cell death—TNF upregulates BNIP3 expression. Biochim Biophys Acta. 1793;2009:546–60.
52.
Carrington PE, Sandu C, Wei Y, et al. The structure of FADD and its mode of interaction with procaspase-8. Mol Cell. 2006;22:599–610.PubMedCrossRef
53.
Ghavami S, Hashemi M, Ande SR, et al. Apoptosis and cancer: mutations within caspase genes. J Med Genet. 2009;46:497–510.PubMedCrossRef
54.
Micheau O, Thome M, Schneider P, et al. Gr ̈utter MG. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem. 2002;277:45162–71.PubMedCrossRef
55.
Irmler M, Thome M, Hahne M, et al. Inhibition of death receptors signals by cellular FLIP. Nature. 1997;388:190–5.PubMedCrossRef
56.
57.
Pop C, Oberst A, Drag M, et al. FLIP (L) induces caspase 8 activity in the absence of interdomain caspase 8 cleavage and alters substrate specificity. Biochem J. 2011;433:447–57.PubMedPubMedCentralCrossRef
58.
Chang DW, Xing Z, Pan Y, et al. c-FLIP8(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J. 2002;21:3704–14.PubMedPubMedCentralCrossRef
59.
60.
Qin H, Srinivasula SM, Wu G, Fernandes-Alnemri T, Alnemri ES, Shi Y. Structural basis of procaspase-9 recruitment by the apoptotic protease-activating factor 1. Nature. 1999;399:549–57.PubMedCrossRef
61.
Crook NE, Clem RJ, Miller LK. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J Virol. 1993;67:2168–74.PubMedPubMedCentral
62.
Kaiser WJ, Vucic D, Miller LK. The Drosophila inhibitor of apoptosis D-IAP1 suppresses cell death induced by the caspase drICE. FEBS Lett. 1998;440:243–8.PubMedCrossRef
63.
Eckelman BP, Salvesen GS. The human anti-apoptotic proteins cIAP1 and cIAP2 bind but do not inhibit caspases. J Biol Chem. 2006;281:3254–60.PubMedCrossRef
64.
Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917–22.PubMedCrossRef
65.
Banks DP, Plescia J, Altieri DC, et al. Survivin does not inhibit caspase-3 activity. Blood. 2000;96:4002–3.PubMed
66.
Saleem M, Qadir MI, Perveen N, et al. Inhibitors of apoptotic proteins: new targets for anticancer therapy. Chem Biol Drug Des. 2013;82:243–51.PubMedCrossRef
67.
Sun C, Cai M, Gunasekera AH, et al. NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP. Nature. 1999;401:818–21.PubMedCrossRef
68.
Sun CH, Cai ML, Meadows RP, et al. NMR structure and mutagenesis of the third Bir domain of the inhibitor of apoptosis protein XIAP. J Biol Chem. 2000;275:33777–81.PubMedCrossRef
69.
70.
Salvesen GS, Duckett CS. IAP proteins: blocking the road to death’s door. Nat Rev Mol Cell Biol. 2000;3:401–10.CrossRef
71.
Chai J, Du C, Wu JW, Kyin S, Wang X, Shi Y. Structural and biochemical basis of apoptotic activation by SMAC/DIABLO. Nature. 2000;406:855–62.PubMedCrossRef
72.
Srinivasula SM, Hegde R, Saleh A, et al. A conserved XIAP- interaction motif in caspase-9 and SMAC/DIABLO regulates caspase activity and apoptosis. Nature. 2001;410:112–6.PubMedCrossRef
73.
Yoo NJ, Kim HS, Kim SY, et al. Immunohistochemical analysis of SMAC/DIABLO expression in human carcinomas and sarcomas. APMIS. 2003;111:382–8.PubMedCrossRef
74.
Yang QH, Church-Hajduk R, Ren J, Newton ML, Du C. Omi/HtrA2 catalytic cleavage of inhibitor of apoptosis [IAP] irreversibly inactivates IAPs and facilitates caspase activity in apoptosis. Genes Dev. 2003;17:1487–96.PubMedPubMedCentralCrossRef
75.
Liston P, Fong WG, Kelly NL, et al. Identification of XAF1 as an antagonist of XIAP anti-caspase activity. Nat Cell Biol. 2001;3:28–133.CrossRef
76.
Ma TL, Ni PH, Zhong J, Tan JH, Qiao MM, Jiang SH. Low expression of XIAP- associated factor 1 in human colorectal cancers. Chin J Dig Dis. 2005;6:10–4.PubMedCrossRef
77.
Gross A, Mcdonnell JM, Korsmeyer SJ. Bcl-2 family members and the mitochondria in apoptosis. Genes Dev. 1999;13:1899–911.PubMedCrossRef
78.
Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the Bcl-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;5:49–63.
79.
Pepper C, Bently P. The role of the Bcl-2 family in the modulation of apoptosis. Symp Soc Exp Biol. 2000;52:43–53.PubMed
80.
81.
82.
Camisasca DR, Honorato J, Bernardo V, et al. Expression of Bcl-2 family proteins and associated clinicopathologic factors predict survival outcome in patients with oral squamous cell carcinoma. Oral Oncol. 2009;45:225–33.PubMedCrossRef
83.
Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res. 2009;15:126–1132.CrossRef
84.
Lessene G, Czabotar PE, Colman PM. Bcl-2 family antagonists for cancer therapy. Nat Rev Drug Discov. 2008;7:989–1000.PubMedCrossRef
85.
Hwang JJ, Kuruvilla J, Mendelson D, et al. Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res. 2010;16:4038–45.PubMedPubMedCentralCrossRef
86.
Anderson MA, Huang D, Roberts A. Targeting Bcl2 for the treatment of lymphoid malignancies. Semin Hematol. 2014;51:219–27.PubMedCrossRef
87.
88.
Bhardwaj A, Aggarwal BB. Receptor-mediated choreography of life and death. J Clin Immunol. 2003;23:317–32.PubMedCrossRef
89.
Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Sciences. 1998;281:1305–8.CrossRef
90.
Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119:651–65.PubMedPubMedCentralCrossRef
91.
92.
Fulda S, Debatin KM. Exploiting death receptor signaling pathways for tumor therapy. Biochim Biophys Acta. 1705;2004:27–41.
93.
Bremer E. Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy. ISRN Oncol. 2013;2013:371854.PubMedPubMedCentral
94.
Walczak H, Krammer PH. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res. 2000;256:58–66.PubMedCrossRef
95.
Behrmann I, Walczak H, Krammer PH. Structure of the human APO-1 gene. Eur J Immunol. 1994;24:3057–62.PubMedCrossRef
96.
Tauzin S, Debure L, Moreau JF, Legembre P. CD95-mediated cell signaling in cancer: mutations and posttranslational modulations. Cell Mol Life Sci. 2012;69:1261–77.PubMedCrossRef
97.
Scholl V, Stefanoff CG, Hassan R, Spector N, Renault IZ. Mutations within the 5′ region of FAS/CD95 gene in nodal diffuse large B-cell lymphoma. Leuk Lymphoma. 2007;48:957–63.PubMedCrossRef
98.
Ivanov VN, Ronai Z, Hei TK. Opposite roles of FAP-1 and dynamin in the regulation of Fas (CD95) translocation to the cell surface and susceptibility to Fas ligand-mediated apoptosis. J Biol Chem. 2006;281:1840–52.PubMedCrossRef
99.
Tourneur L, Mistou S, Michiels FM, et al. Loss of FADD protein expression results in a biased Fas-signaling pathway and correlates with the development of tumoral status in thyroid follicular cells. Oncogene. 2003;22:2795–280.PubMedCrossRef
100.
Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene. 2001;20:5865–77.PubMedCrossRef
101.
Yang T, Shi R, Chang L, et al. Huachansu suppresses human bladder cancer cell growth through the Fas/Fasl and TNF-alpha/TNFR1 pathway in vitro and in vivo. J Exp Clin Cancer Res. 2015;34:1–10.CrossRef
102.
Zhong W, Qin S, Zhu B, et al. Oxysterol-binding protein-related protein 8 [ORP8] increases sensitivity of hepatocellular carcinoma cells to Fas-mediated apoptosis. J Biol Chem. 2015;290:8876–87.PubMedPubMedCentralCrossRef
103.
Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996;271:12687–90.PubMedCrossRef
104.
Mahalingam D, Szegezdi E, Keane M, de Jong S, Samali A. TRAIL receptor signalling and modulation: are we on the right TRAIL? Cancer Treat Rev. 2009;35:280–8.PubMedCrossRef
105.
106.
O’Leary L, van der Sloot AM, Reis CR, et al. Decoy receptors block TRAIL sensitivity at a supracellular level: the role of stromal cells in controlling tumour TRAIL sensitivity. Oncogene. 2015. doi:10.​1038/​onc.​2015.​180.PubMed
107.
Woo JK, Kang JH, Jang YS, et al. Evaluation of preventive and therapeutic activity of novel non-steroidal anti-inflammatory drug, CG100649, in colon cancer: increased expression of TNF-related apoptosis-inducing ligand receptors enhance the apoptotic response to combination treatment with TRAIL. Oncol Rep. 2015;3:1947–55.
108.
Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998;273:14363–7.PubMedCrossRef
109.
110.
Lane D, Matte I, Rancourt C, Piché A. Osteoprotegerin [OPG] protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis. J Ovarian Res. 2012;5:34.PubMedPubMedCentralCrossRef
111.
Merino D, Lalaoui N, Morizot A, Solary E, Micheau O. TRAIL in cancer therapy: present and future challenges. Expert Opin Ther Targets. 2007;11:1299–314.PubMedPubMedCentralCrossRef
112.
Gong B, Almasan A. Genomic organization and transcriptional regulation of human APO2/TRAIL gene. Biochem Biophys Res Commun. 2000;278:747–52.PubMedCrossRef
113.
Krieg A, Krieg T, Wenzel M, et al. TRAIL-beta and TRAIL-gamma: two novel splice variants of the human TNF-related apoptosis- inducing ligand (TRAIL) without apoptotic potential. Br J Cancer. 2003;88:918–27.PubMedPubMedCentralCrossRef
114.
Pal R, Gochhait S, Chattopadhyay S, et al. Functional implication of TRAIL-716 C/T promoter polymorphism on its in vitro and in vivo expression and the susceptibility to sporadic breast tumor. Breast Cancer Res Treat. 2012;126:333–43.CrossRef
115.
116.
117.
Lim B, Allen JE, Prabhu VV, Talekar MK, Finnberg NK, El-Deiry WS. Targeting TRAIL in the treatment of cancer: new developments. Expert Opin Ther Targets. 2015;25:1–15.CrossRef
118.
119.
Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10:45–65.PubMedCrossRef
120.
Sedger LM, McDermott MF. TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants—past, present and future. Cytokine Growth Factor Rev. 2014;25:453–72.PubMedCrossRef
121.
Wachter T, Sprick M, Hausmann D, et al. cFLIPL inhibits tumor necrosis factor-related apoptosis-inducing ligand-mediated NF-kappaB activation at the death-inducing signaling complex in human keratinocytes. J Biol Chem. 2004;279:52824–34.PubMedCrossRef
122.
Ebach DR, Riehl TE, Stenson WF. Opposing effects of tumor necrosis factor receptor 1 and 2 in sepsis due to cecal ligation and puncture. Shock. 2005;23:311–8.PubMedCrossRef
123.
Yun HM, Park KR, Kim EC, Han SB, Yoon do Y, Hong JT. IL-32α suppresses colorectal cancer development via TNFR1-mediated death signaling. Oncotarget. 2015;6:9061–72.PubMedPubMedCentralCrossRef
124.
Yu S, Hou D, Chen P, et al. Adenosine induces apoptosis through TNFR1/RIPK1/P38 axis in colon cancer cells. Biochem Biophys Res Commun. 2015;460:759–65.PubMedCrossRef
125.
Bake V, Roesler S, Eckhardt I, Belz K, Fulda S. Synergistic interaction of SMAC mimetic and IFNα to trigger apoptosis in acute myeloid leukemia cells. Cancer Lett. 2014;355:224–31.PubMedCrossRef
126.
Tao YF, Lu J, Du XJ, et al. Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells. BMC Cancer. 2012;26(12):619.CrossRef
127.
128.
Chaturvedi MM, LaPushin R, Aggarwal BB. Tumor necrosis factor and lymphotoxin. Qualitative and quantitative differences in the mediation of early and late cellular response. J Biol Chem. 1994;269:14575–83.PubMed
129.
Etemadi N, Holien JK, Chau D, et al. Lymphotoxin α induces apoptosis, necroptosis and inflammatory signals with the same potency as tumour necrosis factor. FEBS J. 2013;280:5283–97.PubMedCrossRef
130.
de Oliveira JG, Rossi AF, Nizato DM, et al. Influence of functional polymorphisms in TNF-α, IL-8, and IL-10 cytokine genes on mRNA expression levels and risk of gastric cancer. Tumour Biol. 2015 (Epub ahead of print).
131.
Kang YJ, Kim WJ, Bae HU, et al. Involvement of TL1A and DR3 in induction of proinflammatory cytokines and matrix metalloproteinase-9 in atherogenesis. Cytokine. 2005;29:229–35.PubMedCrossRef
132.
Lee SY, Debnath T, Kim SK, Lim BO. Anti-cancer effect and apoptosis induction of cordycepin through DR3 pathway in the human colonic cancer cell HT-29. Food Chem Toxicol. 2013;60:439–47.PubMedCrossRef
133.
Oh SB, Hwang CJ, Song SY, et al. Anti-cancer effect of tectochrysin in NSCLC cells through overexpression of death receptor and inactivation of STAT3. Cancer Lett. 2014;353:95–103.PubMedCrossRef
134.
135.
Surget S, Khoury MP, Bourdon J. Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. Onco Targets Ther. 2013;7:57–68.PubMedPubMedCentral
136.
137.
138.
139.
140.
Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis—the p53 network. J Cell Sci. 2003;116:4077–85.PubMedCrossRef
141.
142.
143.
Jansson MD, Damas ND, Lees M, Jacobsen A, Lund AH. miR-339-5p regulates the p53 tumor-suppressor pathway by targeting MDM2. Oncogene. 2014;34:1908–18.PubMedCrossRef
144.
Yu J, Zhang L. PUMA, a potent killer with or without p53. Oncogene Suppl. 1998;1:S71–83.
145.
Hikisz P, Kiliańska ZM. PUMA, a critical mediator of cell death—one decade on from its discovery. Cell Mol Biol Lett. 2012;17:646–69.PubMedCrossRef
146.
Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem. 2002;277:3247–57.PubMedCrossRef
147.
148.
Mihara M, Erster S, Zaika A, et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell. 2003;11:577–90.PubMedCrossRef
149.
Ha JH, Shin JS, Yoon MK, et al. Dual-site interactions of p53 protein transactivation domain with anti-apoptotic Bcl-2 family proteins reveal a highly convergent mechanism of divergent p53 pathways. J Biol Chem. 2013;288:7387–98.PubMedPubMedCentralCrossRef
150.
Chipuk JE, Kuwana T, Bouchier-Hayes L, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 2004;303:1010–4.PubMedCrossRef
151.
Leu JI, Dumont P, Hafey M, Murphy ME, George DL. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1complex. Nat Cell Biol. 2004;6:443–50.PubMedCrossRef
152.
Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinicaluse. Cold Spring Harb Perspect Biol. 2010;2:a001008.PubMedPubMedCentralCrossRef
153.
Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer. 2009;9:701–13.PubMed
154.
Saleem S, Abbasi ZA, Hameed A, Qureshi NR, Khan MA, Azhar A. Novel p53 codon 240 Ser > Thr coding region mutation in the patients of oral squamous cell carcinoma (OSCC). Tumour Biol. 2014;35:7945–50.PubMedCrossRef
155.
Trbusek M, Smardova J, Malcikova J, et al. Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. J Clin Oncol. 2011;29:2703–8.PubMedCrossRef
156.
Wang S, Zhou M, Ouyang J, Geng Z, Wang Z. Tetraarsenictetrasulfide and arsenic trioxide exert synergistic effects on induction of apoptosis and differentiation in acute promyelocytic leukemia cells. PLoS One. 2015;10:e0130343.PubMedPubMedCentralCrossRef
157.
Gu ZT, Li L, Wu F, et al. Heat stress induced apoptosis is triggered by transcription-independent p53, Ca[2+] dyshomeostasis and the subsequent Bax mitochondrial translocation. Sci Rep. 2015;5:11497.PubMedPubMedCentralCrossRef
158.
Sosin AM, Burger AM, Siddiqi A, Abrams J, Mohammad RM, Al-Katib AM. HDM2 antagonist MI-219 [spiro-oxindole], but not Nutlin-3 [cis-imidazoline], regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas. J Hematol Oncol. 2012;5:57.PubMedPubMedCentralCrossRef
159.
Boeckler FM, Joerger AC, Jaggi G, Rutherford TJ, Veprintsev DB, Fersht AR. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci U S A. 2008;105:10360–5.PubMedPubMedCentralCrossRef
160.
Vermeij R, Leffers N, van der Burg SH, Melief CJ, Daemen T, Nijman HW. Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies. J Biomed Biotechnol. 2011;2011:702146.PubMedPubMedCentralCrossRef
161.
Lima RT, Busacca S, Almeida GM, Gaudino G, Fennell DA, Vasconcelos MH. MicroRNA regulation of core apoptosis pathways in cancer. Eur J Cancer. 2011;47:163–74.PubMedCrossRef
162.
Chen Y, Fu LL, Wen X, et al. Oncogenic and tumor suppressive roles of microRNAs in apoptosis and autophagy. Apoptosis. 2014;19:1177–89.PubMedCrossRef
163.
Acunzo M, Visone R, Romano G, et al. Mir-130a targets MET and induces trail-sensitivity in NSCLC by downregulating mir-221 and 222. Oncogene. 2012;31:634–42.PubMed
164.
Hao J, Zhang C, Zhang A, et al. miR-221/222 is the regulator of Cx43 expression in human glioblastoma cells. Oncol Rep. 2012;27:1504–10.PubMed
165.
Wang P, Zhuang L, Zhang J, et al. The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL. Mol Oncol. 2013;7:334–45.PubMedCrossRef
166.
Qin W, Shi Y, Zhao B, et al. miR-24 regulates apoptosis by targeting the open reading frame (ORF) region of FAF1 in cancer cells. PLoS ONE. 2010;5:e9429.PubMedPubMedCentralCrossRef
167.
Satzger I, Mattern A, Kuettler U, et al. microRNA-21 is upregulated in malignant melanoma and influences apoptosis of melanocytic cells. Exp Dermatol. 2012;21:509–14.PubMedCrossRef
168.
Eto K, Iwatsuki M, Watanabe M, et al. The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab. Ann Surg Oncol. 2013;21:343–50.PubMedCrossRef
169.
170.
Li JH, Xiao X, Zhang YN, et al. MicroRNA miR-886-5p inhibits apoptosis by down-regulating Bax expression in human cervical carcinoma cells. Gynecol Oncol. 2011;120:145–51.PubMedCrossRef
171.
Zhou M, Liu Z, Zhao Y, et al. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem. 2010;285:21496–507.PubMedPubMedCentralCrossRef
172.
Zhang H, Zuo Z, Lu X, Wang L, Wang H, Zhu Z. MiR-25 regulates apoptosis by targeting Bim in human ovarian cancer. Oncol Rep. 2012;27:594–8.PubMed
173.
Gocek E, Wang X, Liu X, Liu CG, Studzinski GP. MicroRNA-32 upregulation by 1,25-dihydroxyvitamin D3 in human myeloid leukemia cells leads to Bim targeting and inhibition of AraC-induced apoptosis. Cancer Res. 2011;71:6230–9.PubMedCrossRef
174.
175.
Tanaka N, Toyooka S, Soh J, et al. Downregulation of microRNA-34 induces cell proliferation and invasion of human mesothelial cells. Oncol Rep. 2013;29:2169–74.PubMed
176.
Shen J, Wan R, Hu G, et al. miR-15b and miR-16 induce the apoptosis of rat activated pancreatic stellate cells by targeting Bcl-2 in vitro. Pancreatology. 2012;12:91–9.PubMedCrossRef
177.
Xu J, Liao X, Wong C. Downregulations of B-cell lymphoma 2 and myeloid cell leukemia sequence 1 by microRNA 153 induce apoptosis in a glioblastoma cell line DBTRG-05MG. Int J Cancer. 2010;126:1029–35.PubMed
178.
Nakano H, Miyazawa T, Kinoshita K, Yamada Y, Yoshida T. Functional screening identifies a microRNA, miR-491 that induces apoptosis by targeting Bcl-X(L) in colorectal cancer cells. Int J Cancer. 2010;127:1072–80.PubMedCrossRef
179.
Shang J, Yang F, Wang Y, et al. Sun S MicroRNA-23a antisense enhances 5-fluorouracil chemosensitivity through APAF-1/caspase-9 apoptotic pathway in colorectal cancer cells. J Cell Biochem. 2014;115:772–84.PubMedCrossRef
180.
181.
Wu JH, Yao YL, Gu T, et al. MiR-421 regulates apoptosis of BGC-823 gastric cancer cells by targeting caspase-3. Asian Pac J Cancer Prev. 2014;15:5463–8.PubMedCrossRef
182.
Hudson RS, Yi M, Esposito D, et al. Microrna-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer. Oncogene. 2013;32:4139–47.PubMedCrossRef
183.
Floyd DH, Zhang Y, Dey BK, et al. Novel anti-apoptotic microRNAs 582–5p and 363 promote human glioblastoma stem cell survival via direct inhibition of caspase 3, caspase 9, and Bim. PLoS One. 2014;9:e96239.PubMedPubMedCentralCrossRef
184.
Tsang WP, Kwok TT. Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis. 2008;13:1215–22.PubMedCrossRef
185.
Zhang J, Du Y, Wu C, et al. Curcumin promotes apoptosis in human lung adenocarcinoma cells through miR-186 signaling pathway. Oncol Rep. 2010;24:1217–23.PubMed
186.
Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008;9:139–50.PubMedCrossRef
187.
Barth BM, Cabot MC, Kester M. Ceramide-based therapeutics for the treatment of cancer. Anti Cancer Agents Med Chem. 2011;11:911–9.CrossRef
188.
Senchenkov A, Litvak DA, Cabot MC. Targeting ceramide metabolism—a strategy for overcoming drug resistance. J Natl Cancer Inst. 2001;93:347–57.PubMedCrossRef
189.
Siskind LJ, Kolesnick RN, Colombini M. Ceramide channels increase the permeability of the mitochondrial outer membrane to small proteins. J Biol Chem. 2002;277:26796–803.PubMedPubMedCentralCrossRef
190.
191.
von Haefen C, Wieder T, Gillissen B, et al. Ceramide induces mitochondrial activation and apoptosis via a Bax-dependent pathway in human carcinoma cells. Oncogene. 2002;21:4009–19.CrossRef
192.
Dumitru CA, Sandalcioglu IE, Wagner M, Weller M, Gulbins E. Lysosomal ceramide mediates gemcitabine-induced death of glioma cells. J Mol Med. 2009;87:1123–32.PubMedCrossRef
193.
Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer: pathogenesis and treatment. Nat Rev Cancer. 2004;4:604–16.PubMedCrossRef
194.
Liu F, Verin AD, Wang P, et al. Differential regulation of sphingosine-1-phosphate- and VEGF-induced endothelial cell chemotaxis. Involvement of G(ialpha2)-linked Rho kinase activity. Am J Respir Cell Mol Biol. 2001;24:711–9.PubMedCrossRef
195.
Radin NS. The development of aggressive cancer: a possible role for sphingolipids. Cancer Investig. 2002;20:779–86.CrossRef
196.
Pchejetski D, Golzio M, Bonhoure E, et al. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res. 2005;65:11667–75.PubMedCrossRef
197.
Beckham TH, Lu P, Jones EE, et al. LCL124, a cationic analog of ceramide, selectively induces pancreatic cancer cell death by accumulating in mitochondria. J Pharmacol Exp Ther. 2013;344(1):167–78.PubMedPubMedCentralCrossRef
198.
Jiang Y, DiVittore NA, Kaiser JM, et al. Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer. Cancer Biol Ther. 2011;12(7):574–85.PubMedPubMedCentralCrossRef
199.
Sorli SC, Colié S, Albinet V, et al. The nonlysosomal β-glucosidase GBA2 promotes endoplasmic reticulum stress and impairs tumorigenicity of human melanoma cells. FASEB J. 2013;27(2):489–98.PubMedCrossRef
200.
Stover TC, Sharma A, Robertson GP, Kester M. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin Cancer Res. 2005;11(9):3465–74.PubMedCrossRef
201.
Beljanski V, Lewis CS, Smith CD. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biol Ther. 2011;11(5):524–34.PubMedPubMedCentralCrossRef
202.
Adan-Gokbulut A, Kartal-Yandim M, Iskender G, Baran Y. Novel agents targeting bioactive sphingolipids for the treatment of cancer. Curr Med Chem. 2013;20(1):108–22.PubMedCrossRef
203.
Coward J, Ambrosini G, Musi E, Truman JP, Haimovitz-Friedman A, Allegood JC. Safingol (L-threo-sphinganine) induces autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway. Autophagy. 2009;5:184–93.PubMedCrossRef
204.
205.
Taouji S, Higa A, Delom F, et al. Phosphorylation of serine palmitoyltransferase long chain-1 (SPTLC1) on tyrosine 164 inhibits its activity and promotes cell survival. J Biol Chem. 2013;288(24):17190–201.PubMedPubMedCentralCrossRef
206.
Huang WC, Tsai CC, Chen CL, et al. Glucosylceramide synthase inhibitor PDMP sensitizes chronic myeloid leukemia T315I mutant to Bcr-Abl inhibitor and cooperatively induces glycogen synthase kinase-3-regulated apoptosis. FASEB J. 2011;25(10):3661–73.PubMedCrossRef
207.
Nica AF, Tsao CC, Watt JC, et al. Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK. Cell Cycle. 2008;7(21):3362–70.PubMedPubMedCentralCrossRef
208.
Camgoz A, Gencer EB, Ural AU, Baran Y. Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance. Leukemia Lymphoma. 2013;54:1279–87.PubMedCrossRef
209.
Baran Y, Bielawski J, Gunduz U, Ogretmen B. Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation. J Cancer Res Clin Oncol. 2011;137:1535–44.PubMedCrossRef
210.
Kartal M, Saydam G, Sahin F, Baran Y. Resveratrol triggers apoptosis through regulating ceramide metabolizing genes in human K562 chronic myeloid leukemia cells. Nutr Cancer. 2011;63(4):637–44.PubMedCrossRef
211.
Cakir Z, Saydam G, Sahin F, Baran Y. The roles of bioactive sphingolipids in resveratrol-induced apoptosis in HL60: acute myeloid leukemia cells. J Cancer Res Clin Oncol. 2011;137(2):279–86.PubMedCrossRef
212.
Camgoz A, Gencer EB, Ural AU, Avcu F, Baran Y. Roles of ceramide synthase and ceramide clearence genes in nilotinib-induced cell death in chronic myeloid leukemia cells. Leukemia Lymphoma. 2011;52:1574–84.PubMedCrossRef
213.
Gencer EB, Ural AU, Avcu F, Baran Y. A novel mechanism of dasatinib-induced apoptosis in chronic myeloid leukemia; ceramide synthase and ceramide clearance genes. Ann Hematol. 2011;90:1265–75.PubMedCrossRef
Metadata
Title
Major apoptotic mechanisms and genes involved in apoptosis
Authors
Yağmur Kiraz
Aysun Adan
Melis Kartal Yandim
Yusuf Baran
Publication date
01-07-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 7/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5035-9

Other articles of this Issue 7/2016

Tumor Biology 7/2016 Go to the issue

Original Article

PIK3CA and PIK3CB silencing by RNAi reverse MDR and inhibit tumorigenic properties in human colorectal carcinoma

Original Article

GRIM-19 inhibition induced autophagy through activation of ERK and HIF-1α not STAT3 in Hela cells

Original Article

SUSD2 is frequently downregulated and functions as a tumor suppressor in RCC and lung cancer

Original Article

Prognostic impact and potential interaction of EGFR and c-Met in the progression of esophageal squamous cell carcinoma

Original Article

SHh-Gli1 signaling pathway promotes cell survival by mediating baculoviral IAP repeat-containing 3 (BIRC3) gene in pancreatic cancer cells

Original Article

The green tea polyphenol EGCG potentiates the antiproliferative activity of sunitinib in human cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits